GenStar, Vascular Genetics to Merge
- Share via
GenStar Therapeutics Corp. and closely held Vascular Genetics Inc. agreed to merge, becoming a biotechnology company focused on gene therapy.
Shareholders of each San Diego firm will own 50% of the new company, to be named Autus Genetics Corp.
Autus plans to focus on developing a gene therapy treatment for heart disease developed by Human Genome Sciences Inc. Human Genome, which owns a 27% stake in Vascular Genetics, will own 15% of the new company. Baxter International Inc., an investor in GenStar, will hold about 15% of Autus.
GenStar shares rose 14 cents to 73 cents on the American Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
